Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Therapeutic trade-offs between ide-cel and cilta-cel in RRMM: A meta-analytic comparison of efficacy and adverse events

Mobina Golmohammadi, Shahzad Raza, Doris Hansen et al. Nov 03, 2025 pp. 7606-7606 10.1182/blood-2025-7606

Abstract Background: Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone...

DNA methylation instability as a biomarker to predict resistance or progression to advanced disease Phase following tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Yael Morgenstern, Oyeronke Ayansola, Jae-Sook Ahn et al. Nov 03, 2025 pp. 7274-7274 10.1182/blood-2025-7274

Abstract Introduction DNA methylation occurs at defined CpG sites across the genome and plays a critical role in regulating gene expression....

Prognostic relevance of epigenetic regulation of drug pharmacology and myeloid genes in pediatric AML

Naifah Alshameri, Francisco Marchi, Soheil Meshinchi et al. Nov 03, 2025 pp. 1712-1712 10.1182/blood-2025-1712

Abstract Introduction: The dysregulation of DNA methylation in acute myeloid leukemia (AML) significantly changes the regulation and express...

Severe toxicities in survivors of pediatric and adolescent acute lymphoblastic lymphoma: A population-based study in Ontario, Canada

Karen Arane, Cindy Lau, Qing Li et al. Nov 03, 2025 pp. 3332-3332 10.1182/blood-2025-3332

Abstract Cure rates for children, adolescents, and young adults with acute lymphoblastic leukemia (ALL) have improved dramatically and have...

Elevated TIM3 expression on bone marrow T cells drives immune dysfunction in early relapsed blood cancer after allogeneic hematopoietic stem cell transplantation

Thi Thuy Duong Pham, Wonhyoung Seo, Su-Young Choi et al. Nov 03, 2025 pp. 6027-6027 10.1182/blood-2025-6027

Abstract Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curative option for hematologic malignancies,...

Real-world treatment patterns and outcomes in patients with myelofibrosis who presented with thrombocytopenia and anemia at initiation of pacritinib treatment

Naveen Pemmaraju, Abiola Oladapo, Michael Marrone et al. Nov 03, 2025 pp. 725-725 10.1182/blood-2025-725

Abstract Background: The co-occurrence of thrombocytopenia and anemia (bicytopenia) in patients (pts) with myelofibrosis (MF) is a therapeut...

Low-dose post-transplant cyclophosphamide for GvHD prophylaxis in haploidentical stem cell transplantation: A systematic review of efficacy, toxicity, and survival outcomes

Areez Shafqat, Omar Ahmad, Mohammed Omer et al. Nov 03, 2025 pp. 7775-7775 10.1182/blood-2025-7775

Abstract Background: Haploidentical allogeneic stem cell transplantation (haplo-SCT) has been a transformative option for patients lacking m...

Zip-code drug conjugates (ZDCs): Ctdna-guided therapy shows strong efficacy and low toxicity in vitro and In Vivo

Munevver Cinar, Andrey Pisarev, Pavan Puvvula et al. Nov 03, 2025 pp. 5703-5703 10.1182/blood-2025-5703

Abstract Multiple myeloma (MM) is a malignancy marked by the clonal expansion of plasma cells. Despite therapeutic advances, MM remains incu...

Face validity of progressive rank criteria to identify high-utilizer sickle cell patients in an adult sickle cell disease medical home

Wally Smith, Daniel Sop, Yue Zhang et al. Nov 03, 2025 pp. 2594-2594 10.1182/blood-2025-2594

Abstract Background Community-based case management within a sickle cell disease (SCD) medical home offers the potential to reduce costly em...

Meta-analysis confirms venetoclax plus decitabine as a frontline game-changer in elderly AML (Acute Myeloid Leukemia)

Anubhuti Sharma, Arundhati Sharma, Simranpreet Singh Daid et al. Nov 03, 2025 pp. 8192-8192 10.1182/blood-2025-8192

Abstract Background: Acute Myeloid Leukemia (AML) in elderly patients is characterized by poor clinical outcomes, limite...

Post-treatment loss of MMR vaccine immunity in multiple myeloma patients following autologous stem cell transplantation: A retrospective cohort analysis

Sidharth Mahajan, Jorgena Kosti, Imran Puthawala et al. Nov 03, 2025 pp. 5795-5795 10.1182/blood-2025-5795

Abstract Background Multiple myeloma (MM), a clonal plasma cell malignancy, accounts for approximately 10% of all hemato...

Tracking fellowship competitiveness in hematology-oncology: Insights from nrmp match data (2014–2025)

Ruqqiya Mustaqeem, Sana Mulla Nov 03, 2025 pp. 8213-8213 10.1182/blood-2025-8213

Abstract Background This study evaluates trends in Hematology-Oncology fellowship match outcomes from 2014 to 2025 using...

SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma

Chan Cheah, Monique Menzies Wojtowicz, Catherine Thieblemont et al. Nov 03, 2025 pp. 3747-3747 10.1182/blood-2025-3747

Abstract Background and Significance: Management of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL) is challenging. Surovat...

Patient outcomes for sickle cell disease with support staff-driven interventions: A scoping review

Samantha Steffin, Mary Sehl, Shenise Gilyard et al. Nov 03, 2025 pp. 7892-7892 10.1182/blood-2025-7892

Abstract Background: Sickle cell disease (SCD) is a chronic condition characterized by progressive organ dysfunction and significant early m...

Evaluation of CAR-T access barriers in Washington and Alaska: A single-center experience prior to implementing program capacity expansion

Melinda Biernacki, Agie Cole, Kausar Abukar et al. Nov 03, 2025 pp. 6202-6202 10.1182/blood-2025-6202

Abstract Background: Chimeric antigen receptor T cell therapies (CAR-T), while transformative, are expensive, require specialty center treat...

Comparative analysis of prophylaxis with 1:1 ratio pdVWF/FVIII concentrate vs. recombinant VWF in type 3 von willebrand disease adults in the United States: Clinical and economic perspective

Robert Sidonio, Jr., Nathan Connell, Fernando Corrales-Medina et al. Nov 03, 2025 pp. 4857-4857 10.1182/blood-2025-4857

Abstract Background Prophylactic treatment with von Willebrand factor (VWF) concentrates is recommended for patients wit...

Ruxolitinib and cardiovascular outcomes among patients with myelofibrosis

Orly Leiva, Steven Soo, Olivia Liu et al. Nov 03, 2025 pp. 3796-3796 10.1182/blood-2025-3796

Abstract Introduction: Myelofibrosis (MF) is an advanced phenotype of Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) char...

Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study)

Sascha Tuchman, Susan Geyer, Garth Nelson et al. Nov 03, 2025 pp. 2289-2289 10.1182/blood-2025-2289

Abstract Background: Multiple myeloma (MM) remains incurable, though key advances such as chimeric antigen receptor T-cells (CAR-T) and immu...

Optimizing classical hematology referrals: Development and early evaluation of an enhanced referral intervention

Ashley Price, Jacqueline Poston, Neil Zakai et al. Nov 03, 2025 pp. 6175-6175 10.1182/blood-2025-6175

Abstract Background Classical hematology has a shortage of providers, leading to extended wait times from the time of referral to the initia...

Autoimmune hemolytic anemia: An underrecognized contributor to anemia and hemolysis in babesiosis infection

Annsea Park, Valentina Restrepo, Christopher Tormey et al. Nov 03, 2025 pp. 2693-2693 10.1182/blood-2025-2693

Abstract Background: Babesiosis is a zoonotic illness transmitted by ticks and caused by intraerythrocytic protozoa belonging to the genus B...

Deep learning-based tumor microenvironment profiling predicts CAR-t efficacy and guides combinatorial immunotherapy in B-cell lymphoma

Shaojie Wu, Jiatong Wang, Jiaxiu Li Nov 03, 2025 pp. 5331-5331 10.1182/blood-2025-5331

Abstract Introduction CAR-T cell therapy efficacy in B-cell lymphoma remains limited by treatment resistance. To address this fundamental ch...

A multi-site break through cancer pilot study testing the feasibility and safety of therapeutic intervention for patients with high-risk clonal cytopenia of undetermined significance (CCUS)

Danielle Hammond, Amy DeZern, Kelly Chien et al. Nov 03, 2025 pp. 3160-3160 10.1182/blood-2025-3160

Abstract Background Clonal hematopoiesis (CH), the age-related clonal expansion of blood cells, is often caused by somatic mutations genes as...

Photodynamic immunotherapy using adu-S100-modified nanoparticles combined with icb to treat triple-negative breast cancer

Guohui Yu, Yingxin Xiong, Penghui Wang et al. Nov 03, 2025 pp. 7649-7649 10.1182/blood-2025-7649

Abstract Background Tumor immunotherapy is an important cancer treatment that stimulates or modulates the immune system to improve the intri...

Optimizing immunity to pneumococcus by vaccination with pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T cell immunotherapy

M Bakri Hammami, Dasom (Caroline) Lee, Lindsey Raymond et al. Nov 03, 2025 pp. 4166-4166 10.1182/blood-2025-4166

Abstract Background: Patients with relapsed or refractory B-cell non-Hodgkin's lymphoma undergoing CD19-targeted CAR T-cell therapy (CAR-T)...

A real-world study on first-line early switch to kpd regimen in the treatment of multiple myeloma patients with suboptimal induction efficacy or intolerance

Xu Ji, Yanliang Bai, jiangxue Hou et al. Nov 03, 2025 pp. 7548-7548 10.1182/blood-2025-7548

Abstract Objective: To evaluate the efficacy and safety of early switch to the KPD regimen (carfilzomib, pomalidomide, dexamethasone) in mul...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page